Skip to main content

IncyteCARES for Jakafi is a program for residents
of the United States and Puerto Rico.

What Is IncyteCARES?

Watch this short video to see how our IncyteCARES for Jakafi team can help you get started with your medicine and provide as-needed support for managing various challenges along the way.

Video play icon

Video: What Is IncyteCARES?

Narrator: Welcome to IncyteCARES, a support program for people prescribed an Incyte medicine.

We know that managing a health condition can be challenging. That’s why our IncyteCARES team is here—to help you get started with your medicine and to be your quick-call source when you need support along the way.

Onscreen text: Not all patients are eligible to receive all IncyteCARES services.

Narrator: Once you’re enrolled in IncyteCARES, a team member will call you. We’ll go over your insurance coverage for your medicine, so there are no surprises.

Onscreen text: Not all patients qualify. Terms and conditions apply.

Narrator: If needed, we can see if you might qualify for savings or financial assistance to help you afford your medicine. We can send your prescription to a specialty pharmacy for you, since regular pharmacies don’t carry all Incyte medicines. And we can help arrange regular deliveries. Simple, right?

From there, IncyteCARES is your on-call support team, offering guidance and easy access to resources that can help with certain challenges.

Onscreen text: Some services are not provided for all Incyte medicines.

Narrator: For instance, we can help connect you to resources for emotional support. Whether you’d like to meet with a professional counselor, find a support group, or be paired with someone who knows firsthand what you’re going through.

Have questions about your medicine or maybe a change in your insurance? Our trained representatives can provide reliable answers quickly.

Onscreen text (appears in chat bubbles from an IncyteCARES representative):
Try This
No problem
Glad to help
Just a few questions...

Narrator: If you need help with travel to medical appointments, tips for taking care of yourself, or advice for managing family, home, or work challenges, we can connect you to those types of resources as well. And so much more!

When it comes to medical advice, you have your doctor’s care. For other kinds of support, IncyteCARES may be able to help.

Ask your Healthcare Professional to enroll you, or call us today!

Connect Today! Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

Onscreen text: This video is sponsored by Incyte. Incyte and the Incyte logo are registered trademarks of Incyte.

©2022, Incyte. MAT-INC-01627  05/22

phone support icon
Need Help?

Our IncyteCARES for Jakafi team is available

Monday through Friday,
8 AM–8 PM ET

Call us at
1-855-452-5234

Video: What Is IncyteCARES?

Narrator: Welcome to IncyteCARES, a support program for people prescribed an Incyte medicine.

We know that managing a health condition can be challenging. That’s why our IncyteCARES team is here—to help you get started with your medicine and to be your quick-call source when you need support along the way.

Onscreen text: Not all patients are eligible to receive all IncyteCARES services.

Narrator: Once you’re enrolled in IncyteCARES, a team member will call you. We’ll go over your insurance coverage for your medicine, so there are no surprises.

Onscreen text: Not all patients qualify. Terms and conditions apply.

Narrator: If needed, we can see if you might qualify for savings or financial assistance to help you afford your medicine. We can send your prescription to a specialty pharmacy for you, since regular pharmacies don’t carry all Incyte medicines. And we can help arrange regular deliveries. Simple, right?

From there, IncyteCARES is your on-call support team, offering guidance and easy access to resources that can help with certain challenges.

Onscreen text: Some services are not provided for all Incyte medicines.

Narrator: For instance, we can help connect you to resources for emotional support. Whether you’d like to meet with a professional counselor, find a support group, or be paired with someone who knows firsthand what you’re going through.

Have questions about your medicine or maybe a change in your insurance? Our trained representatives can provide reliable answers quickly.

Onscreen text (appears in chat bubbles from an IncyteCARES representative):
Try This
No problem
Glad to help
Just a few questions...

Narrator: If you need help with travel to medical appointments, tips for taking care of yourself, or advice for managing family, home, or work challenges, we can connect you to those types of resources as well. And so much more!

When it comes to medical advice, you have your doctor’s care. For other kinds of support, IncyteCARES may be able to help.

Ask your Healthcare Professional to enroll you, or call us today!

Connect Today! Call IncyteCARES at 1-855-452-5234, Monday through Friday, 8 AM–8 PM ET.

Onscreen text: This video is sponsored by Incyte. Incyte and the Incyte logo are registered trademarks of Incyte.

©2022, Incyte. MAT-INC-01627  05/22

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Jakafi is used to treat adults and children 12 years of age and older with chronic graft-versus-host disease (GVHD) who have taken one or two types of treatments and they did not work well enough.

IMPORTANT SAFETY INFORMATION

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause low platelet, red blood cell, and white blood cell counts. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will do a blood test to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Cancer: Some people have had certain types of non-melanoma skin cancers during treatment with Jakafi. Your healthcare provider will regularly check your skin during your treatment with Jakafi. Tell your healthcare provider if you develop any new or changing skin lesions during treatment with Jakafi.

Increases in cholesterol: You may have changes in your blood cholesterol levels during treatment with Jakafi. Your healthcare provider will do blood tests to check your cholesterol levels about every 8 to 12 weeks after you start taking Jakafi, and as needed.

Increased risk of major cardiovascular events such as heart attack, stroke or death in people who have cardiovascular risk factors and who are current or past smokers while using another JAK inhibitor to treat rheumatoid arthritis: Get emergency help right away if you have any symptoms of a heart attack or stroke while taking Jakafi, including: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back, severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw, pain or discomfort in your arms, back, neck, jaw, or stomach, shortness of breath with or without chest discomfort, breaking out in a cold sweat, nausea or vomiting, feeling lightheaded, weakness in one part or on one side of your body, slurred speech

Increased risk of blood clots: Blood clots in the veins of your legs (deep vein thrombosis, DVT) or lungs (pulmonary embolism, PE) have happened in people taking another JAK inhibitor for rheumatoid arthritis and may be life-threatening. Tell your healthcare provider right away if you have any signs and symptoms of blood clots during treatment with Jakafi, including: swelling, pain, or tenderness in one or both legs, sudden, unexplained chest or upper back pain, shortness of breath or difficulty breathing

Possible increased risk of new (secondary) cancers: People who take another JAK inhibitor for rheumatoid arthritis have an increased risk of new (secondary) cancers, including lymphoma and other cancers. People who smoke or who smoked in the past have an added risk of new cancers.

The most common side effects of Jakafi include: for certain types of myelofibrosis (MF) and polycythemia vera (PV) – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; for acute GVHD – low platelet counts, low red or white blood cell counts, infections, and swelling; and for chronic GVHD – low red blood cell or platelet counts and infections including viral infections.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Call your doctor for medical advice about side effects.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had low white or red blood cell counts, have or had tuberculosis (TB) or have been in close contact with someone who has TB, had shingles (herpes zoster), have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had cancer, are a current or past smoker, had a blood clot, heart attack, other heart problems or stroke, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.